OnKure Therapeutics (OKUR) Non-Current Assets (2020 - 2026)
OnKure Therapeutics' (OKUR) quarterly Non-Current Assets came in at $1.2 million in Q1 2026, down 29.12% YoY from $1.7 million in Q1 2025, and down 5.16% on a QoQ basis from $1.3 million in Q4 2025.
OnKure Therapeutics (OKUR) Non-Current Assets (2020 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 7 years of Non-Current Assets data on file, last reported at $1.2 million in Q1 2026.
- Quarterly Non-Current Assets fell 29.12% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (up 6.62% YoY) and the FY2025 annual result came in at $1.3 million, down 32.88% from the prior year.
- Non-Current Assets declined to $1.2 million in Q1 2026, from $1.3 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $2.0 million in Q4 2023 to a low of $646000.0 in Q3 2024.
- A 5-year average of $1.5 million and a median of $1.6 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 879.75% — and 2024, when it slumped 61.51%.
- Tracing OKUR's Non-Current Assets over 5 years: stood at $1.8 million in 2022, then advanced by 7.6% to $2.0 million in 2023, then dropped by 3.25% to $1.9 million in 2024, then plunged by 32.88% to $1.3 million in 2025, then fell by 5.16% to $1.2 million in 2026.
- The last three Non-Current Assets figures came in at $1.2 million (Q1 2026), $1.3 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | OnKure Therapeutics | 196.98 Mn | 20.60 Mn | - | 1.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.68 Mn |
| Mar 31, 2026 | 1.21 Mn |
| Dec 31, 2025 | 1.28 Mn |
| Sep 30, 2025 | 1.31 Mn |
| Jun 30, 2025 | 1.52 Mn |
| Mar 31, 2025 | 1.71 Mn |
| Dec 31, 2024 | 1.90 Mn |
| Sep 30, 2024 | 646,000.00 |
| Jun 30, 2024 | 727,000.00 |
| Mar 31, 2024 | 712,000.00 |
| Dec 31, 2023 | 1.97 Mn |
| Sep 30, 2023 | 1.62 Mn |
| Jun 30, 2023 | 1.72 Mn |
| Mar 31, 2023 | 1.85 Mn |
| Dec 31, 2022 | 1.83 Mn |
| Sep 30, 2022 | 1.51 Mn |
| Jun 30, 2022 | 1.60 Mn |
| Mar 31, 2022 | 1.70 Mn |
| Dec 31, 2021 | 290,000.00 |
| Sep 30, 2021 | 278,000.00 |